Loading
Life sciences · Journal article
npj Breast Cancer · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metaplastic breast carcinoma (MpBC) is a rare, histologically heterogeneous breast cancer typically treated with regimens developed for triple-negative breast cancer (TNBC), despite distinct biology and insufficient response to standard therapy. MpBC is defined by differentiation of malignant epithelial cells toward non-glandular lineages, reflecting a plasticity that complicates biomarker interpretation and distinguishes it from non-metaplastic TNBC. In this review, we cover MpBC histopathology, biology, and therapeutic development, calling for dedicated clinical investigation that recognizes MpBC as a biologically distinct entity.